Previous 10 | Next 10 |
VALENCIA, Calif. and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, toda...
AVITA Medical ( NASDAQ: RCEL ) on Monday said it had submitted a premarket approval supplement application to the U.S. FDA for its RECELL system to expand the indication to include soft tissue repair. The company's RECELL system had previously been approved by the FDA for the treatmen...
VALENCIA, Calif., and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced tod...
VALENCIA, Calif., and MELBOURNE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announc...
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites ...
AVITA Medical, Inc. (RCEL) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Jim Corbett - Chief Executive Officer Michael Holder - Chief Financial Officer Conference C...
AVITA Medical press release ( NASDAQ: RCEL ): Q3 GAAP EPS of -$0.22 beats by $0.11 . Revenue of $9.09M (+29.5% Y/Y) beats by $2.04M . Turning to guidance, full year 2022 commercial revenue (excluding BARDA revenues) is expected to be $33.0-34.0 million, an incr...
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “ Company ”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular ther...
Avita Medical ( NASDAQ: RCEL ) ( OTCPK:AVHHL ) said its RECELL System for soft tissue repair met the the co-primary goals as a result of updated analysis of data from its clinical trial. RECELL achieved statistically significant donor sparing over control, one m...
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today an...
News, Short Squeeze, Breakout and More Instantly...
VALENCIA, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its second quarter 2024 financia...
VALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the Joseph M. Still Burn Center at Doctors Hosp...
2024-06-02 14:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...